Section 27: Vitamins and Minerals

ascorbic acid tablet, 50 mg

¤ergocalciferol capsule or tablet, 1.25 mg

(50 000 IU)

oral solution,

250 µg/ml (10 000 IU/ml)

iodine (8) iodized oil, 1 ml (480 mg iodine),

0.5 ml (240 mg iodine) in

ampoule (oral or injectable)

solution, 0.57 ml, (308 mg iodine)

in dispenser bottle

capsule, 200 mg

¤nicotinamide tablet, 50 mg

pyridoxine tablet, 25 mg (hydrochloride)

¤retinol sugar-coated tablet, 10 000 IU

(as palmitate) (5.5 mg)

capsule, 200 000 IU (as

palmitate) (110 mg)

oral oily solution,

100 000 IU/ml in multidose

dispenser (as palmitate)

water-miscible injection,

100 000 IU (as palmitate)

(55 mg) in 2-ml ampoule

riboflavin tablet, 5 mg

¤sodium fluoride in any appropriate formulation

thiamine tablet, 50 mg (hydrochloride)

Complementary drug

calcium gluconate (C) (2, 8) injection,100 mg/ml

in 10-ml ampoule

¤ Example of a therapeutic group. Various drugs can serve as alternatives.

Essential Drugs

The following changes in the WHO Model List were approved by the WHO Expert Committee on

the Use of Essential Drugs which met in December 1999. The report of the meeting will be

published in the WHO Technical Report Series.

Deletions: , albumin (human); antiscorpion sera.

Additions: acetylcysteine; rifampicin + isoniazid + pyrazinamide + ethambutol; nevirapine; artesunate;

chlorambucil; daunorubicin; ethanol; iohexol.

Replacements: fluconazole to replace ketoconazole; prazosin to replace doxazosin.